<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en" article-type="rapid-communication" dtd-version="2.3">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">molbank</journal-id>
      <journal-title>Molbank</journal-title>
      <abbrev-journal-title abbrev-type="publisher">Molbank</abbrev-journal-title>
      <abbrev-journal-title abbrev-type="pubmed">Molbank</abbrev-journal-title>
      <issn pub-type="epub">1422-8599</issn>
      <publisher>
        <publisher-name>MDPI</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.3390/M801</article-id>
      <article-id pub-id-type="publisher-id">molbank-2013-M801</article-id>
      <article-categories>
        <subj-group>
          <subject>Short Note</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>(<italic>R</italic>)-7-(Azepan-3-ylamino)-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid Hydrochloride</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Xia</surname>
            <given-names>Zhengjun</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>Zaixin</given-names>
          </name>
          <xref rid="c1-molbank-2013-M801" ref-type="corresp">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yu</surname>
            <given-names>Shuitao</given-names>
          </name>
        </contrib>
      </contrib-group>
      <aff id="af1-molbank-2013-M801">R&amp;D Center, Jiangsu Yabang Pharmaceutical Group, Changzhou 213200, China</aff>
      <author-notes>
        <corresp id="c1-molbank-2013-M801"><label>*</label> Author to whom correspondence should be addressed; E-Mail: <email>zaixin_chen@163.com</email>.</corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>22</day>
        <month>05</month>
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="collection">
        <month>06</month>
        <year>2013</year>
      </pub-date>
      <volume>2013</volume>
      <issue>2</issue>
      <elocation-id>M801</elocation-id>
      <history>
        <date date-type="received">
          <day>15</day>
          <month>04</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>13</day>
          <month>05</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2013 by the authors; licensee MDPI, Basel, Switzerland.</copyright-statement>
        <copyright-year>2013</copyright-year>
        <license>
          <p>This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).</p>
        </license>
      </permissions>
      <abstract>
        <p>In this paper (<italic>R</italic>)-7-(azepan-3-ylamino)-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride <bold>1</bold> was isolated and identified as the <italic>N</italic>-substituted regioisomer of besifloxacin, which has been synthesized from the reaction of 8-chloro-1-cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid <bold>3</bold> with (<italic>R</italic>)-tert-butyl 3-aminoazepane-1-carboxylate <bold>2</bold> in acetonitrile as solvent in 37% yield. The chemical structure of compound <bold>1</bold> was established on the basis of <sup>1</sup>H-NMR, <sup>13</sup>C-NMR, mass spectrometry data and elemental analysis.</p>
      </abstract>
      <kwd-group>
        <kwd>besifloxacin</kwd>
        <kwd><italic>N</italic>-substituted regioisomer</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
      <p>Besifloxacin, (+)-7-[(3<italic>R</italic>)-3-aminohexahydro-1H-azepin-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride, developed by SS Pharmaceutical (SSP) Co. Ltd. (<xref ref-type="fig" rid="molbank-2013-M801-f001">Figure 1</xref>), was a fourth-generation fluoroquinolone antibiotic [<xref ref-type="bibr" rid="B1-molbank-2013-M801">1</xref>,<xref ref-type="bibr" rid="B2-molbank-2013-M801">2</xref>,<xref ref-type="bibr" rid="B3-molbank-2013-M801">3</xref>,<xref ref-type="bibr" rid="B4-molbank-2013-M801">4</xref>,<xref ref-type="bibr" rid="B5-molbank-2013-M801">5</xref>]. Besifloxacin hydrochloride eye drop was used to treat bacterial conjunctivitis caused by aerobic and facultative Gram-positive microorganisms and aerobic and facultative Gram-negative microorganisms.</p>
      <p>Recently, we found a new compound <bold>1</bold>, (<italic>R</italic>)<bold>-</bold>7-(azepan-3-ylamino)-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride was always present during the synthesis of besifloxacin. It was found that <bold>1</bold> was the <italic>N</italic>-substituted regioisomer of besifloxacin.</p>
      <p>As a part of our research programme on besifloxacin, we report herein the synthesis of the compound <bold>1</bold> through 8-chloro-1-cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid <bold>3</bold> with (<italic>R</italic>)-tert-butyl 3-aminoazepane-1-carboxylate <bold>2</bold> in acetonitrile in the presence of catalytic amounts of triethylamine (<xref ref-type="scheme" rid="molbank-2013-M801-sch001">Scheme 1</xref>). And then it was deprotected with hydrochloric acid to get the target compound <bold>1</bold> [<xref ref-type="bibr" rid="B6-molbank-2013-M801">6</xref>,<xref ref-type="bibr" rid="B7-molbank-2013-M801">7</xref>,<xref ref-type="bibr" rid="B8-molbank-2013-M801">8</xref>]. The total yield was 37%.</p>
      <p>The <sup>1</sup>H-NMR spectrum of compound <bold>1</bold> was different from besifloxacin. The <sup>1</sup>H-NMR spectrum of compound <bold>1</bold> showed a doublet located at &#x3B4; 6.20 ppm (<italic>J</italic> = 9.1 Hz )which was assigned to the one H-11 proton of -NH-. A singlet was located at &#x3B4; 9.72 ppm indicated two H-14 protons of the amine hydrochloride. The <sup>1</sup>H-NMR spectrum of besifloxacin showed a singlet located at &#x3B4; 8.23 ppm which was assigned to the three H-23' protons of the amine hydrochloride.</p>
    <sec sec-type="methods">
      <title>Experimental</title>
      <p><sup>1</sup>H-NMR and <sup>13</sup>C-NMR spectra were obtained using a Bruker Avance AV-500 spectrometer (Bruker BioSpin GmbH, Karlsruhe, Germany) and were recorded at 500 MHz and 125 MHz respectively. All the experiments were carried out in DMSO-<italic>d</italic><sub>6</sub>. Chemical shifts are expressed in ppm (&#x3B4;) with tetramethylsilane (TMS) as an internal standard.</p>
      <p>The 8-chloro-1-cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid <bold>3</bold> [<xref ref-type="bibr" rid="B9-molbank-2013-M801">9</xref>] and (<italic>R</italic>)-tert-butyl 3-aminoazepane-1-carboxylate <bold>2</bold> [<xref ref-type="bibr" rid="B10-molbank-2013-M801">10</xref>] were obtained by R&amp;D Center, Jiangsu Yabang Pharmaceutical Group.</p>
      <p>To a solution of 8-chloro-1-cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid <bold>3</bold> (3.00 g, 10 mmol), in dry acetonitrile (15 mL) was added to triethylamine (2.00 g, 20 mmol) at 0 &#xB0;C. After 15 min, a solution of (<italic>R</italic>)-tert-butyl 3-aminoazepane-1-carboxylate <bold>2</bold> (2.14 g, 10 mmol) in anhydrous acetonitrile (5 mL) was added and the mixture was refluxed for 5 h. Then the mixture was concentrated to dryness, dissolved in CH<sub>2</sub>Cl<sub>2</sub> (30 mL), washed with brine (15 mL &#xD7; 3), followed by concentrated and recrystallized from 95% ethanol to give a white solid. The white solid dissolved in 4 mol/L HCl-ethanol solution, then heated at 37 &#xB0;C for 2 h. After concentrated to dryness and recrystallized by 95% ethanol to give compound <bold>1</bold> as pale yellowish-white powder.</p>
      <p>Yield: 37%; m.p.: 224&#x2013;225 &#xB0;C pale yellowish-white powder.</p>
    </sec>
    <sec>
      <title>Structural Characterization</title>
      <p><sup>1</sup>H-NMR (500 MHz, DMSO-<italic>d<sub>6</sub></italic>): &#x3B4; ppm: 14.73 (H-23, s, 1H), 9.72 (H-14, s, 2H), 8.69 (H-7, s, 1H), 7.79 (H-1, d, <italic>J</italic> = 13.1 Hz, 1H), 6.20 (H-11, d, <italic>J</italic> = 9.1 Hz, 1H), 4.37 (H-12 and H-19, m, 2H), 3.38 (H-13, m, 2H), 3.23 (H-15, m, 1H), 3.09 (H-15, m, 1H), 2.14 (H-18, m, 1H), 1.94 (H-16 and H-18, m, 2H), 1.84 (H-16 and H-17, m, 2H), 1.60 (H-17, m, 1H), 1.23 (H-20 or H-21, m, 2H), 1.03 (H-20 or H-21, m, 2H). </p>
      <p><sup>13</sup>C-NMR(125 MHz, DMSO-<italic>d<sub>6</sub></italic>): &#x3B4; ppm: 175.6 (C-9), 165.4 (C-22), 151.7 (C-7), 150.6 (C-2), 148.7 (C-3), 139.0 (C-5), 137.3 (C-4), 117.8 (C-10), 110.3 (C-1), 107.0 (C-8), 52.9 (C-12), 50.1 (C-13), 46.2 (C-15), 41.3 (C-19), 34.0 (C-18), 24.9 (C-16), 21.6 (C-17), 10.9 (C-20 or C-21). </p>
      <p>FAB-MS, <italic>m/z</italic> = 394.1 (M<sup>+</sup>).</p>
      <p>Elemental analysis: Calculated for C<sub>19</sub>H<sub>21</sub>ClFN<sub>3</sub>O<sub>3</sub><sup>.</sup>HCl: C, 53.03%; H, 5.15%; N, 9.77%; found: C, 52.82%; H, 5.39%; N, 9.50%.</p>
    </sec>
  </body>
  <back>
    <app-group>
    <app id="app1-molbank-2013-M801">
      <title>Supplementary materials</title>
    <supplementary-material id="molbank-2013-M801-s001" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2013-M801-s001-mod.mol">
	<label>Supplementary File 1</label>
	</supplementary-material>
	<supplementary-material id="molbank-2013-M801-s002" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2013-M801-s001.mol">
	<label>Supplementary File 2</label>
	</supplementary-material>
	<supplementary-material id="molbank-2013-M801-s003" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2013-M801-s002.pdf">
	<label>Supplementary File 3</label>
	</supplementary-material>
   </app>
    </app-group>
	<ack>
      <title>Acknowledgements</title>
      <p>Authors are thankful to China Pharmaceutical University for providing the spectra data. The sample of compound <bold>1</bold>, <bold>2</bold>, and <bold>3</bold> were provided by R&amp;D Center, Jiangsu Yabang Pharmaceutical Group is also acknowledged.</p>
    </ack>
    <ref-list>
      <title>References and Notes</title>
      <ref id="B1-molbank-2013-M801">
        <label>1.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haas</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Pillar</surname>
              <given-names>C.M.</given-names>
            </name>
            <name>
              <surname>Zurenko</surname>
              <given-names>G.E.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Brunner</surname>
              <given-names>L.S.</given-names>
            </name>
            <name>
              <surname>Morris</surname>
              <given-names>T.W.</given-names>
            </name>
          </person-group>
          <article-title>Besifloxacin, a novel fluoroquinolone, has broad-spectrum <italic>in vitro</italic> activity against acrobic and anaerobic bacteria</article-title>
          <source>Antimicrob Agents Chemother.</source>
          <year>2009</year>
          <volume>53</volume>
          <fpage>3552</fpage>
          <lpage>3560</lpage>
          <pub-id pub-id-type="doi">10.1128/AAC.00418-09</pub-id>
          <pub-id pub-id-type="pmid">19506065</pub-id>
        </citation>
      </ref>
      <ref id="B2-molbank-2013-M801">
        <label>2.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tepedino</surname>
              <given-names>M.E.</given-names>
            </name>
            <name>
              <surname>Heller</surname>
              <given-names>W.H.</given-names>
            </name>
            <name>
              <surname>Usner</surname>
              <given-names>D.W.</given-names>
            </name>
            <name>
              <surname>Brunner</surname>
              <given-names>L.S.</given-names>
            </name>
            <name>
              <surname>Morris</surname>
              <given-names>T.W.</given-names>
            </name>
            <name>
              <surname>Haas</surname>
              <given-names>W.</given-names>
            </name>
			<name>
              <surname>Paterno</surname>
              <given-names>M.R.</given-names>
            </name>
			<name>
              <surname>Comstock</surname>
              <given-names>T.L.</given-names>
            </name>
          </person-group>
          <article-title>Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis</article-title>
          <source>Curr. Med. Res. Opin.</source>
          <year>2009</year>
          <volume>25</volume>
          <fpage>1159</fpage>
          <lpage>1169</lpage>
          <pub-id pub-id-type="doi">10.1185/03007990902837919</pub-id>
          <pub-id pub-id-type="pmid">19323612</pub-id>
        </citation>
      </ref>
      <ref id="B3-molbank-2013-M801">
        <label>3.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Karpecki</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>DePaolis</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Hunter</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>White</surname>
              <given-names>E.M.</given-names>
            </name>
            <name>
              <surname>Rigel</surname>
              <given-names>L.</given-names>
            </name>
			<name>
              <surname>Brunner</surname>
              <given-names>L.S.</given-names>
            </name>
			<name>
              <surname>Usner</surname>
              <given-names>D.W.</given-names>
            </name>
			<name>
              <surname>Paterno</surname>
              <given-names>M.R.</given-names>
            </name>
			<name>
              <surname>Comstock</surname>
              <given-names>T.L.</given-names>
            </name>
          </person-group>
          <article-title>Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study</article-title>
          <source>Clin. Ther.</source>
          <year>2009</year>
          <volume>31</volume>
          <fpage>514</fpage>
          <lpage>526</lpage>
          <pub-id pub-id-type="doi">10.1016/j.clinthera.2009.03.010</pub-id>
          <pub-id pub-id-type="pmid">19393842</pub-id>
        </citation>
      </ref>
      <ref id="B4-molbank-2013-M801">
        <label>4.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McDonald</surname>
              <given-names>M.B.</given-names>
            </name>
            <name>
              <surname>Protzko</surname>
              <given-names>E.E.</given-names>
            </name>
            <name>
              <surname>Brunner</surname>
              <given-names>L.S.</given-names>
            </name>
            <name>
              <surname>Morris</surname>
              <given-names>T.W.</given-names>
            </name>
            <name>
              <surname>Haas</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Paterno</surname>
              <given-names>M.R.</given-names>
            </name>
            <name>
              <surname>Comstock</surname>
              <given-names>T.L.</given-names>
            </name>
            <name>
              <surname>Usner</surname>
              <given-names>D.W.</given-names>
            </name>
          </person-group>
          <article-title>Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis</article-title>
          <source>Ophthalmology</source>
          <year>2009</year>
          <volume>116</volume>
          <fpage>1615</fpage>
          <lpage>1623</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ophtha.2009.05.014</pub-id>
          <pub-id pub-id-type="pmid">19643483</pub-id>
        </citation>
      </ref>
      <ref id="B5-molbank-2013-M801">
        <label>5.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yoshida</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Pratzer</surname>
              <given-names>K.A.</given-names>
            </name>
            <name>
              <surname>Stark</surname>
              <given-names>W.J.</given-names>
            </name>
          </person-group>
          <article-title>Aqueous penetration of moxifloxacin 0.5% ophthalmic solution and besifloxacin 0.6% ophthalmic suspension in cataract surgery patients</article-title>
          <source>J. Cataract Refract. Surg.</source>
          <year>2010</year>
          <volume>36</volume>
          <fpage>1499</fpage>
          <lpage>1502</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jcrs.2010.04.030</pub-id>
          <pub-id pub-id-type="pmid">20692561</pub-id>
        </citation>
      </ref>
      <ref id="B6-molbank-2013-M801">
        <label>6.</label>
        <citation citation-type="patent">
          <person-group person-group-type="author">
            <name>
              <surname>Harms</surname>
              <given-names>A.E.</given-names>
            </name>
            <name>
              <surname>Ramakrishnan</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Soni</surname>
              <given-names>A.K.</given-names>
            </name>
          </person-group>
          <article-title>Quinolone Carboxylic Acids, Derivatives Thereof, and Methods of Making and Using Same</article-title>
          <source>U.S. Patent</source>
          <patent>8252783</patent>
          <day>17</day>
          <month>September</month>
          <year>2009</year>
        </citation>
      </ref>
      <ref id="B7-molbank-2013-M801">
        <label>7.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pellegata</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Pinza</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Pifferi</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>An improved synthesis of &#x3B3;-, &#x3B4;-, and &#x3B5;-lactams</article-title>
          <source>Synthesis</source>
          <year>1978</year>
          <volume>1978</volume>
          <fpage>614</fpage>
          <lpage>616</lpage>
          <pub-id pub-id-type="doi">10.1055/s-1978-24834</pub-id>
        </citation>
      </ref>
      <ref id="B8-molbank-2013-M801">
        <label>8.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Boyle</surname>
              <given-names>W.J.</given-names>
            </name>
            <name>
              <surname>Sifniades</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Peppen</surname>
              <given-names>J.F.</given-names>
            </name>
          </person-group>
          <article-title>Asymmetric transformation of &#x3B1;-amino-&#x3B5;-caprolactam, a ysine precursor</article-title>
          <source>J. Org. Chem.</source>
          <year>1979</year>
          <volume>44</volume>
          <fpage>4841</fpage>
          <lpage>4847</lpage>
          <pub-id pub-id-type="doi">10.1021/jo00394a021</pub-id>
        </citation>
      </ref>
      <ref id="B9-molbank-2013-M801">
        <label>9.</label>
        <citation citation-type="patent">
          <person-group person-group-type="author">
            <name>
              <surname>Irakura</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Suzue</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Murayama</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Hirai</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Ishizaki</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Quinolinecarboxylic Acid Derivatives and Process for Their Preparation</article-title>
          <source>Eur. Pat. Appl.</source>
          <patent>0195841</patent>
          <day>1</day>
          <month>October</month>
		  <year>1986</year>
        </citation>
      </ref>
      <ref id="B10-molbank-2013-M801">
        <label>10.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sanchez</surname>
              <given-names>J.P.</given-names>
            </name>
            <name>
              <surname>Domagala</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Hagen</surname>
              <given-names>S.E.</given-names>
            </name>
            <name>
              <surname>Heifetz</surname>
              <given-names>C.L.</given-names>
            </name>
            <name>
              <surname>Hutt</surname>
              <given-names>M.P.</given-names>
            </name>
            <name>
              <surname>Nichols</surname>
              <given-names>J.B.</given-names>
            </name>
            <name>
              <surname>Trehan</surname>
              <given-names>A.K.</given-names>
            </name>
          </person-group>
          <article-title>Quinolone antibacterial agents. Synthesis and structure-activity relationships of 8-substituted quinoline-3-carboxylic acids and 1,8-naphthyridine-3-carboxylic acids</article-title>
          <source>J. Med. Chem.</source>
          <year>1988</year>
          <volume>31</volume>
          <fpage>983</fpage>
          <lpage>991</lpage>
          <pub-id pub-id-type="doi">10.1021/jm00400a016</pub-id>
          <pub-id pub-id-type="pmid">3361584</pub-id>
        </citation>
      </ref>
    </ref-list>
    <sec sec-type="display-objects">
      <title>Figure and Scheme</title>
      <fig id="molbank-2013-M801-f001" position="float">
        <label>Figure 1</label>
        <caption>
          <p>The structure of besifloxacin.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2013-M801-g001.tif"/>
      </fig>
      <fig id="molbank-2013-M801-sch001" position="float">
        <object-id pub-id-type="pii">molbank-2013-M801-sch001_Scheme 1</object-id>
        <label>Scheme 1</label>
        <caption>
          <p>Synthesis of (<italic>R</italic>)<bold>-</bold>7-(azepan-3-ylamino)-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2013-M801-sch001.tif"/>
      </fig>
    </sec>
  </back>
</article>
